Plasmablastic pituitary lymphoma in a patient with human immunodeficiency virus: brief review of the literature and clinical case report

Cover Page

Cite item

Full Text

Abstract

Plasmoblastic lymphoma is a rare, aggressive B-cell malignancy with poor long-term survival. Plasmoblastic lymphoma occurs most commonly in patients infected with human immunodeficiency virus (HIV), but cases associated with solid organ transplantation have also been reported, less commonly plasmoblastic lymphoma registers in immunocompetent patients. The disease is more common in male patients (75 %) aged from 8 to 62 years (median age 50 years), and most often the tumor lesions are localized in the oral cavity. Rare localizations of plasmoblastic lymphoma include pleura, testicles, mammary glands, lungs, and skin. As casuistic areas of lesions, the central nervous system can be noted.

The article describes a clinical case of HIV-positive pediatric patient with rare plasmoblastic lymphoma of chiasmosellar zone. The disease was complicated with secondary hypocorticism and hypotyreosis, a deficiency of somatotrophic hormone and diabetes insipidus.

About the authors

D. V. Martynov

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

Author for correspondence.
Email: martynovmed@yandex.ru
ORCID iD: 0000-0003-0814-4941

Denis V. Martynov 

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

T. T. Valiev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia;
I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University);
Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

ORCID iD: 0000-0002-1469-2365

23 Kashirskoe Shosse, Moscow 115522,

Build. 2, 8 Trubetskaya St., Moscow 119991,

2/1 Barrikadnaya St., Moscow 125993

Russian Federation

A. A. Odzharova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0003-3576-6156

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

Yu. E. Ryabukhina

Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0001-8443-8816

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

P. A. Zeynalova

I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia (Sechenov University);
Clinical Hospital “Lapino” of the “Mother and Child” Group of companies

ORCID iD: 0000-0003-1564-424X

Build. 2, 8 Trubetskaya St., Moscow 119991,

111 1st Uspenskoe Shosse, Lapino, Moscow region 143081

Russian Federation

S. N. Mikhailova

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0002-9502-072X

23 Kashirskoe Shosse, Moscow 115522

Russian Federation

References

  1. Delecluse H.J., Anagnostopoulos I., Dallenbach F. et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood 1997;89(4):1413–20.
  2. Morscio J., Dierickx D., Nijs J. et al. Clinicopathologic comparison of plasmablastic lymphoma in HIV-positive, immunocompetent, and posttransplant patients: single-center series of 25 cases and meta-analysis of 277 reported cases. Am J Surg Pathol 2014;38(7):875–86. doi: 10.1097/PAS.0000000000000234
  3. Lopez A., Abrisqueta P. Plasmablastic lymphoma: current perspectives. Blood Lymphat Cancer 2018;8:63–70. doi: 10.2147/BLCTT.S142814
  4. Montes-Moreno S., Gonzalez-Medina A.R., Rodriguez-Pinilla S.M. et al. Aggressive large B-cell lymphoma with plasma cell differentiation: immunohistochemical characterization of plasmablastic lymphoma and diffuse large B-cell lymphoma with partial plasmablastic phenotype. Haematologica 2010;95(8):1342–9. doi: 10.3324/haematol.2009.016113
  5. Firsova M.V., Solov’ev M.V., Kovrigina A.M. et al. Plasmablastic lymphoma with primary impairment of bone marrow in a HIVnegative patient: a literature review and a case report. Klinicheskaya onkogematologiya = Clinical Oncohematology 2022;15(4):356–64. (In Russ.). doi: 10.21320/2500-2139-2022-15-4-356-364
  6. Dong H.Y., Scadden D.T., de Leval L. et al. Plasmablastic lymphoma in HIV-positive patients: an aggressive Epstein–Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol 2005;29(12):1633–41. doi: 10.1097/01.pas.0000173023.02724.1f
  7. Song M.K., Chung J.S., Shin H.J. et al. Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 2012;91(5):697–703. doi: 10.1007/s00277-011-1357-2
  8. Teruya-Feldstein J., Chiao E., Filippa D.A. et al. CD20-negative large-cell lymphoma with plasmablastic features: a clinically heterogenous spectrum in both HIV-positive and -negative patients. Ann Oncol 2004;15(11):1673–9. doi: 10.1093/annonc/mdh399
  9. Loghavi S., Alayed K., Aladily T.N. et al. Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patients. J Hematol Oncol 2015;8:65. doi: 10.1186/s13045-015-0163-z
  10. Castillo J.J., Bibas M., Miranda R.N. The biology and treatment of plasmablastic lymphoma. Blood 2015;125(15):2323–30. doi: 10.1182/blood-2014-10-567479
  11. Tchernonog E., Faurie P., Coppo P. et al. Clinical characteristics and prognostic factors of plasmablastic lymphoma patients: analysis of 135 patients from the LYSA group. Ann Oncol 2017;28(4):843–8. doi: 10.1093/annonc/mdw684
  12. Qunaj L., Castillo J.J., Olszewski A.J. Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base. Leuk Lymphoma 2018;59(6):1375–83. doi: 10.1080/10428194.2017.1387912
  13. Castillo J.J., Furman M., Beltrán B.E. et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer 2012;118(21):5270–7. doi: 10.1002/cncr.27551
  14. Chapman J., Gentles A.J., Sujoy V. et al. Gene expression analysis of plasmablastic lymphoma identifies downregulation of B-cell receptor signaling and additional unique transcriptional programs. Leukemia 2015;29(11):2270–3. doi: 10.1038/leu.2015.109
  15. Valera A., Balagué O., Colomo L. et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol 2010;34(11):1686–94. doi: 10.1097/PAS.0b013e3181f3e29f
  16. Bogusz A.M., Seegmiller A.C., Garcia R. et al. Plasmablastic lymphomas with MYC/IgH rearrangement: report of three cases and review of the literature. Am J Clin Pathol 2009;132(4):597–605. doi: 10.1309/AJCPFUR1BK0UODTS
  17. Valera A., Colomo L., Martínez A. et al. ALK-positive large B-cell lymphomas express a terminal B-cell differentiation program and activated STAT3 but lack MYC rearrangements. Mod Pathol 2013;26(10):1329–37. doi: 10.1038/modpathol.2013.73
  18. Montes-Moreno S., Martinez-Magunacelaya N., ZecchiniBarrese T. et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol 2017;30(1):85–94. doi: 10.1038/modpathol.2016.162
  19. Xia Y., Xu-Monette Z.Y., Tzankov A. et al. Loss of PRDM1/ BLIMP-1 function contributes to poor prognosis of activated B-cell-like diffuse large B-cell lymphoma. Leukemia 2017;31(3):625–36. doi: 10.1038/leu.2016.243
  20. Colomo L., Loong F., Rives S. et al. Diffuse large B-cell lymphomas with plasmablastic differentiation represent a heterogeneous group of disease entities. Am J Surg Pathol 2004;28(6):736–47. doi: 10.1097/01.pas.0000126781.87158.e3
  21. Harmon C.M., Smith L.B. Plasmablastic lymphoma: a review of clinicopathologic features and differential diagnosis. Arch Pathol Lab Med 2016;140(10):1074–8. doi: 10.5858/arpa.2016-0232-RA
  22. Marini C., Baldaia H., Trigo F. et al. Transformation of a previously diagnosed diffuse large B-cell lymphoma to plasmablastic lymphoma. Am J Hematol 2016;91(8):E324. doi: 10.1002/ajh.24375
  23. Castillo J.J., Winer E.S., Stachurski D. et al. Clinical and pathological differences between human immunodeficiency virus-positive and human immunodeficiency virus-negative patients with plasmablastic lymphoma. Leuk Lymphoma 2010;51(11): 2047–53. doi: 10.3109/10428194.2010.516040
  24. Baryakh E.A., Kremenetskaya A.M., Kravchenko S.K. et al. New short high-intensity treatment protocol for adult Burkitt-like lymphoma BPL-M-04: interim results. Gematologiya i transfuziologiya = Hematology and Transfusiology 2006;51(6):3–11. (In Russ.).
  25. Castillo J.J., Guerrero-Garcia T., Baldini F. et al. Bortezomib plus EPOCH is effective as frontline treatment in patients with plasmablastic lymphoma. Br J Haematol 2019;184(4):679–82. doi: 10.1111/bjh.15156
  26. Schommers P., Wyen C., Hentrich M. et al. Poor outcome of HIVinfected patients with plasmablastic lymphoma: results from the German AIDS-related lymphoma cohort study. AIDS 2013;27(5):842–5. doi: 10.1097/QAD.0b013e32835e069d

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36928 от  21.07.2009.